VTv Gross Profit from 2010 to 2025

VTVT Stock

USD 16.57 0.07 0.42%

VTv Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit vTv Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2013-12-31

Previous Quarter

-23 K

Current Value

17 K

Quarterly Volatility

4.3 M

Yuan Drop

Covid

Check VTv Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VTv Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.5 K, Interest Expense of 0.0 or Selling General Administrative of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.57, Dividend Yield of 0.0 or PTB Ratio of 6.86. VTv financial statements analysis is a perfect complement when working with VTv Therapeutics Valuation or Volatility modules.

Check out the analysis of VTv Therapeutics Correlation against competitors.

For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.

Latest VTv Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of vTv Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of vTv Therapeutics minus its cost of goods sold. It is profit before VTv Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. VTv Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VTv Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (9.93 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

VTv Gross Profit Regression Statistics

	Arithmetic Mean	(14,511,322)
	Coefficient Of Variation	(103.67)
	Mean Deviation	12,236,968
	Median	(12,355,000)
	Standard Deviation	15,043,931
	Sample Variance	226.3T
	Range	49M
	R-Value	0.61
	Mean Square Error	151T
	R-Squared	0.38
	Significance	0.01
	Slope	1,941,336
	Total Sum of Squares	3394.8T

VTv Gross Profit History

	2025	1.1 M
	2024	1 M
	2023	-13.6 M
	2022	1.9 M
	2021	3.9 M
	2020	-4.6 M
	2019	-12.4 M

Other Fundumenentals of vTv Therapeutics

Gross Profit Margin

VTv Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Capital Surpluse	Common Stock	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.29	-0.05	-0.69	0.45	0.27	-0.18	0.27	-0.36	-0.16	0.95	-0.28	-0.32	0.29	-0.27	0.57	-0.08	-0.05	0.21	-0.13	0.12	-0.01
Total Stockholder Equity	0.29		-0.2	-0.75	0.69	-0.07	-0.4	0.21	0.1	-0.99	0.46	-0.63	-0.84	0.95	-0.62	0.24	0.72	0.15	-0.61	0.76	0.52	0.01
Current Deferred Revenue	-0.05	-0.2		0.04	-0.19	0.61	0.49	0.34	0.16	0.2	-0.08	-0.19	-0.14	-0.07	-0.1	0.13	-0.29	-0.09	0.59	-0.31	-0.24	-0.04
Net Debt	-0.69	-0.75	0.04		-0.43	-0.05	-0.03	-0.21	0.05	0.67	-0.82	0.84	0.87	-0.85	0.64	-0.49	-0.44	-0.01	0.32	-0.46	-0.41	0.07
Retained Earnings	0.45	0.69	-0.19	-0.43		0.41	-0.74	0.21	0.14	-0.65	0.45	-0.12	-0.43	0.53	-0.32	0.6	0.15	0.22	-0.2	0.15	-0.09	0.19
Accounts Payable	0.27	-0.07	0.61	-0.05	0.41		0.03	0.4	0.15	0.11	0.18	0.02	-0.09	-0.06	-0.21	0.71	-0.55	-0.09	0.61	-0.57	-0.62	0.0
Long Term Debt	-0.18	-0.4	0.49	-0.03	-0.74	0.03		0.13	0.02	0.39	-0.16	-0.4	-0.08	-0.13	0.04	-0.08	-0.13	-0.07	0.22	-0.12	-0.04	-0.04
Net Receivables	0.27	0.21	0.34	-0.21	0.21	0.4	0.13		-0.21	-0.18	0.24	-0.24	-0.31	0.24	-0.08	0.18	0.08	0.38	0.2	-0.01	0.12	0.41
Short Term Investments	-0.36	0.1	0.16	0.05	0.14	0.15	0.02	-0.21		-0.16	-0.33	-0.16	-0.24	0.17	-0.11	0.33	-0.04	0.13	-0.32	0.07	-0.33	0.07
Total Liab	-0.16	-0.99	0.2	0.67	-0.65	0.11	0.39	-0.18	-0.16		-0.33	0.61	0.82	-0.93	0.59	-0.17	-0.76	-0.17	0.67	-0.81	-0.51	-0.02
Total Current Assets	0.95	0.46	-0.08	-0.82	0.45	0.18	-0.16	0.24	-0.33	-0.33		-0.42	-0.48	0.46	-0.49	0.55	0.05	-0.17	0.1	0.08	0.31	-0.16
Short Term Debt	-0.28	-0.63	-0.19	0.84	-0.12	0.02	-0.4	-0.24	-0.16	0.61	-0.42		0.93	-0.84	0.54	-0.29	-0.55	-0.16	0.43	-0.56	-0.35	-0.05
Property Plant Equipment	-0.32	-0.84	-0.14	0.87	-0.43	-0.09	-0.08	-0.31	-0.24	0.82	-0.48	0.93		-0.96	0.66	-0.39	-0.6	-0.15	0.47	-0.62	-0.38	-0.02
Net Tangible Assets	0.29	0.95	-0.07	-0.85	0.53	-0.06	-0.13	0.24	0.17	-0.93	0.46	-0.84	-0.96		-0.63	0.28	0.72	0.2	-0.61	0.74	0.47	0.06
Long Term Investments	-0.27	-0.62	-0.1	0.64	-0.32	-0.21	0.04	-0.08	-0.11	0.59	-0.49	0.54	0.66	-0.63		-0.4	-0.3	0.54	0.2	-0.43	-0.35	0.63
Short Long Term Debt	0.57	0.24	0.13	-0.49	0.6	0.71	-0.08	0.18	0.33	-0.17	0.55	-0.29	-0.39	0.28	-0.4		-0.35	-0.02	0.15	-0.27	-0.43	0.01
Capital Surpluse	-0.08	0.72	-0.29	-0.44	0.15	-0.55	-0.13	0.08	-0.04	-0.76	0.05	-0.55	-0.6	0.72	-0.3	-0.35		0.22	-0.81	0.9	0.68	0.06
Common Stock	-0.05	0.15	-0.09	-0.01	0.22	-0.09	-0.07	0.38	0.13	-0.17	-0.17	-0.16	-0.15	0.2	0.54	-0.02	0.22		-0.31	0.11	-0.12	0.98
Long Term Debt Total	0.21	-0.61	0.59	0.32	-0.2	0.61	0.22	0.2	-0.32	0.67	0.1	0.43	0.47	-0.61	0.2	0.15	-0.81	-0.31		-0.81	-0.4	-0.15
Net Invested Capital	-0.13	0.76	-0.31	-0.46	0.15	-0.57	-0.12	-0.01	0.07	-0.81	0.08	-0.56	-0.62	0.74	-0.43	-0.27	0.9	0.11	-0.81		0.76	-0.06
Net Working Capital	0.12	0.52	-0.24	-0.41	-0.09	-0.62	-0.04	0.12	-0.33	-0.51	0.31	-0.35	-0.38	0.47	-0.35	-0.43	0.68	-0.12	-0.4	0.76		-0.22
Capital Stock	-0.01	0.01	-0.04	0.07	0.19	0.0	-0.04	0.41	0.07	-0.02	-0.16	-0.05	-0.02	0.06	0.63	0.01	0.06	0.98	-0.15	-0.06	-0.22

Click cells to compare fundamentals

About VTv Therapeutics Financial Statements

VTv Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although VTv Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in VTv Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on VTv Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	1 M	1.1 M
Gross Profit Margin	0.86	0.90

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for VTv Stock Analysis

When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC